Company Analysis
Sign in

Arcus Biosciences, Inc. (RCUS)

NYSE: RCUS · Pharmaceutical Preparations · Hayward, CA · filing with the SEC since 2017
Full chart Alerts Compare
Grade4.7
◀ Past 5.3● Present 4.9▶ Future 3.8
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

36 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Arcus Biosciences, Inc.’s names, not what it holds today.

Patents granted
36
36 utility, 1976 to Dec 31, 2025
Granted in 2025
11
Against 9 in 2024 and 6 in 2023
Applications published
52
9 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals23
Organic fine chemistry7
Biotechnology3
Medical technology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Arcus Biosciences, Inc. its own name
US, as the owner printed on each patent
36 granted
11 published
ARCUS BIOSCIENCES, INC. its own name
named as the applicant on its applications, in US
0 granted
41 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 4, 202512,459,967Modulators of 5′-nucleotidase, ecto and the use thereofPharmaceuticalsArcus Biosciences, Inc.
Oct 28, 202512,453,738Treatment of oncogene-driven cancersPharmaceuticalsArcus Biosciences, Inc.
Oct 7, 202512,433,836Parenterally administered immune enhancing drugsPharmaceuticalsArcus Biosciences, Inc.
Sep 16, 202512,415,854Antibodies to TIGITBiotechnologyArcus Biosciences, Inc.
Sep 9, 202512,410,1702,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compoundsMedical technologyArcus Biosciences, Inc.
Aug 12, 202512,384,773Thiazole compounds and methods of use thereofPharmaceuticalsArcus Biosciences, Inc.
May 27, 202512,310,965Treatment of cancer utilizing an identified adenosine fingerprintPharmaceuticalsArcus Biosciences, Inc.
Apr 22, 202512,281,136Crystalline forms of a CD73 inhibitor and uses thereofPharmaceuticalsArcus Biosciences, Inc.
Feb 18, 202512,226,425Inhibitors of ARG1 and/or ARG2PharmaceuticalsArcus Biosciences, Inc.
Jan 14, 202512,195,482Compounds as inhibitors of AXLOrganic fine chemistryArcus Biosciences, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 11, 20252025/0375447TREATMENT OF CANCER UTILIZING AN IDENTIFIED ADENOSINE FINGERPRINTPharmaceuticalsARCUS BIOSCIENCES, INC.
Oct 16, 20252025/0319113INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASEPharmaceuticalsARCUS BIOSCIENCES, INC.
Aug 7, 20252025/0249115COMBINATION THERAPY FOR TREATING TUMOR ANTIGEN EXPRESSING CANCERSPharmaceuticalsARCUS BIOSCIENCES, INC.
Jul 17, 20252025/0230173SALT FORMS OF AN AXL INHIBITOROrganic fine chemistryArcus Biosciences, Inc.
Jul 3, 20252025/0214930TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHAOrganic fine chemistryArcus Biosciences, Inc.
Jun 5, 20252025/0179176ANTI-TIGIT ANTIBODIES AND USES OF THE SAMEPharmaceuticalsARCUS BIOSCIENCES, INC.
May 8, 20252025/0145606THIAZOLE COMPOUNDS AND METHODS OF USE THEREOFPharmaceuticalsArcus Biosciences, Inc. · patent 12,384,773 granted from it
Mar 13, 20252025/0084178ANTI-CD39 ANTIBODIES AND USE THEREOFPharmaceuticalsArcus Biosciences, Inc.
Jan 9, 20252025/0011318CBL-B INHIBITORS AND METHODS OF USE THEREOFPharmaceuticalsArcus Biosciences, Inc.
Dec 26, 20242024/0425526COMPOUNDS AS INHIBITORS OF AXLOrganic fine chemistryArcus Biosciences, Inc. · patent 12,195,482 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 13 · Organic fine chemistry 6 · Biotechnology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton RCUS · research, not advice